Nuvo Pharmaceuticals™ Announces 2019 First Quarter Results

Tuesday, May 14, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Three Months ended

March 31, 2019

Three Months ended

March 31, 2018

in thousands

$

$

Net income (loss)

(7,404)

(169)

Add back:

Income tax expense (recovery)

54

(174)

Net interest expense (income)

1,930

(21)

Depreciation and amortization

2,434

614

EBITDA

(2,986)

250

Add:

Amounts billed to customers for existing contract assets

2,562

93

Stock-based compensation

126

308

Inventory step-up expense

1,215

-

Other Expenses (Income):

Change in fair value of derivative liabilities

5,213

-

Change in fair value of contingent and variable consideration

72

83

Foreign currency loss (gain)

(978)

(158)

Adjusted EBITDA

5,224

576



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store